Showing results (331-340 of 368) with videos related to
Sort By:
Pageof 37
Cancer Discovery|February 2, 2019
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune RecognitionDaisuke Ennishi, Katsuyoshi Takata, Wendy Béguelin, et al.Leukemia|December 30, 2015
Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cellsO A Guryanova, Y K Lieu, F E Garrett-Bakelman, et al.Nature Communications|November 2, 2024
ChromaFold predicts the 3D contact map from single-cell chromatin accessibilityVianne R Gao, Rui Yang, Arnav Das, et al.Cell|July 4, 2020
TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory FateLeandro Venturutti, Matt Teater, Andrew Zhai, et al.Nature|December 10, 2020
H1 histones control the epigenetic landscape by local chromatin compactionMichael A Willcockson, Sean E Healton, Cary N Weiss, et al.Cancer Discovery|May 12, 2019
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AMLCihangir Duy, Matt Teater, Francine E Garrett-Bakelman, et al.Nature Medicine|September 15, 2015
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma developmentAna Ortega-Molina, Isaac W Boss, Andres Canela, et al.Cancer Discovery|October 31, 2012
Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemiaHuimin Geng, Sarah Brennan, Thomas A Milne, et al.Cancer Cell|February 21, 2025
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer modelsPatrizia Porazzi, Siena Nason, Ziqi Yang, et al.Nature Cancer|February 11, 2021
The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencingSara Parsa, Ana Ortega-Molina, Hsia-Yuan Ying, et al.Pageof 37